FDA approves 1st-of-its-kind chronic hives treatment
The FDA has approved Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms are inadequately controlled with H1 antihistamines. Rhapsido is the first treatment approved for symptomatic dermographism, according to an Oct. 7 news release. The oral selective BTK inhibitor is also the only prescription treatment approved for both chronic spontaneous urticaria and symptomatic […] The post FDA approves 1st-of-its-kind chronic hives treatment appeared fir...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.